Companies: 10,795·Total market cap: $144.5T
Gain Therapeutics, Inc.

Gain Therapeutics, Inc.

GANXNASDAQHealthcare● Active
$1.69
$-0.01(-0.59%)
Market Cap$72085324
P/E Ratio
52W High$4.34
52W Low$1.41
Overview

Gain Therapeutics, Inc. (GANX) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · GANX · as of Jun 9, 2026

Key Statistics

EPS (TTM)$-0.58ganx eps ttm · ganx earnings per shareEarnings history
PE Ratio (TTM)ganx pe ratio ttm · ganx price to earningsPE Ratio deep dive
Revenue (TTM)0.00ganx revenue ttm · ganx annual revenueFull revenue history
Dividend YieldNo Dividenddoes ganx pay dividends · ganx dividend yieldDividend history
Shares Outstanding33.0Mganx shares outstanding · ganx floatShares outstanding history
Next EarningsAug 11, 2026Est.ganx earnings date · ganx next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$0.00
202320242025
gain therapeutics, inc. revenue · ganx revenue 2025
FY 2025Net Income-$20.2M▲ +1.23% YoY
202320242025
gain therapeutics, inc. net income · ganx profit 2025
FY 2025EPS$-0.61▲ +31.46% YoY
202320242025
ganx eps · gain therapeutics, inc. earnings per share 2025
TTM:Revenue: $0.00Net Income: -$21.2MEPS: $-0.58View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy8 analystsis ganx a buy · ganx analyst rating
Strong Buy
0
Buy
7
Hold
1
Sell
0
Strong Sell
0
12-Month Price Target
$10.00Low
$1.69Current
$10.00Avg Target491.72% upside
$10.00High
ganx price target · ganx 12 month forecast

Total: 8 · Buy rate: 87.5%

The GANX analyst consensus is Buy, based on ratings from 8 Wall Street analysts over the past 3 months. The average 12-month price target is $10.00, representing +491.72% upside from the current price of $1.69.

Stock Performance

Full History
1D-0.59%
1W-7.65%
1M-7.14%
3M-44.59%
YTD-47.52%
1Y-11.52%
5Y-84.13%

About Gain Therapeutics, Inc.

CEOGene Mack
IPO DateMar 19, 2021
Employees23
CountryUS

Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its effort…

what is gain therapeutics, inc. · ganx stock overview · gain therapeutics, inc. company profile · who is gain therapeutics, inc. ceo · ganx NASDAQ · gain therapeutics, inc. headquarters · gain therapeutics, inc. business segments

About Stock Overview & Key Data

Gain Therapeutics, Inc. (GANX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Mar 19, 2021. As of the latest trading session, GANX stock price is $1.69, with a market capitalization of $72.1M. The stock has returned -11.52% over the past 12 months and -47.52% year-to-date.

According to 8 Wall Street analysts, the consensus rating for Gain Therapeutics, Inc. stock is Buy, with an average 12-month price target of $10.00. In fiscal year 2025, Gain Therapeutics, Inc. reported revenue of — and net income of -$20.2M. For detailed data — including Gain Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Gain Therapeutics, Inc. (GANX) stock price is $1.69. The stock is traded on NASDAQ under the ticker symbol GANX. The 52-week range is $1.41 – $4.34.

GANX stock priceGANX quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 9, 2026Not investment advice